The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example
Published version of a preprint
Abstract
One of the key objectives of oncology first-in-human trials has often been to establish the maximum tolerated dose (MTD). However, targeted therapies might not exhibit dose-limiting toxicities (DLT) at doses significantly higher than sufficiently active doses, and there is frequently a limited ability to objectively quantify adverse events. Thus, while MTD-based determination of recommended phase II dose may have yielded appropriate dosing for some cytotoxics, targeted therapeutics (including monoclonal antibodies and/or immunotherapies) sometimes need alternative or complementary strategies to help identify dose ranges for a randomized dose-ranging study. One complementary strategy is to define a biologically efficacious dose (BED) using an “effect marker.” An effect marker could be a target engagement, pharmacodynamic, or disease progression marker (change in tumor size for solid tumors or bone marrow blast count for some hematologic tumors). Although the concept of BED has been discussed extensively, we review specific examples in which the approach influenced oncology clinical development. Data extracted from the literature and the examples support improving dose selection strategies to benefit patients, providers, and the biopharmaceutical industry. Although the examples illustrate key contributions of effect markers in dose selection, no one-size-fits-all approach to dosing can be justified. Higher-than-optimal dosing can increase toxicity in later trials (and in clinical use), which can have a negative impact on efficacy (via lower adherence or direct sequelae of toxicities). Proper dose selection in oncology should follow a multifactorial decision process leading to a randomized, dose-ranging study instead of a single phase II dose. Clin Cancer Res; 22(6); 1318–24. ©2015 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An alternative strategy focuses on identifying a biologically effective dose based on an array of efficacy markers, such as target engagement, pharmacodynamic markers, and, for bispecific therapeutics, trimer formation. 7 , 11 , 12”
From Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas (2022) · cites this paper as [7]
In the citing paper
“However, for targeted therapeutics (e.g., mAbs, bsAbs), dose‐limiting toxicities may not occur until doses are considerably higher than effective doses, thereby complicating the decision criteria for stopping dose escalation. 7”
From Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas (2022) · cites this paper as [7]
In the citing paper
“Therefore, employing MTD‐based strategies to identify the RP2D can sometimes lead to selection of a dose that is much higher than a sufficiently effective dose. 7”
From Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas (2022) · cites this paper as [7]
Citations
Cites
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446 · cited 2×
“An overall response rate of 57% and an estimated probability of 6month PFS of 72% were reported (33).”
BackgroundCombining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586 · cited 1×
“, crizotinib) and, possibly, combination therapies (39).”
Cabozantinib in Progressive Medullary Thyroid Cancer
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217 · cited 1×
“Although lower exposure did not reduce progression-free survival (PFS), higher exposure was associated with earlier dose reduction; at the 140-mg dose 69% of patients had dose holds and 79% of subjects reduced their doses (7, 8).”
BackgroundDose Escalation Methods in Phase I Cancer Clinical Trials
Le Tourneau, C., Lee, J. J., & Siu, L. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp079 · Cited by 867
Issa, J.-P. J., Garcia-Manero, G., Giles, F. J., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C. S., Cortes, J., et al. (2004) · Blood · doi:10.1182/blood-2003-03-0687 · Cited by 809 · cited 3×
“This time, the focus of clinical trials for acute myelogenous leukemia (AML) was on identifying a dose based on pharmacodynamics rather than an MTD (29).”
BackgroundInfluentialPatnaik, A., Kang, S. P., Rasco, D., Papadopoulos, K. P., Elassaiss-Schaap, J., Beeram, M., Drengler, R., Chen, C., Smith, L., Espino, G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2607 · Cited by 807
Self-citationBaselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D’Andrea, G., Seidman, A., Norton, L., Gunnett, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.904 · Cited by 741 · cited 1×
“For some targeted agents, mechanism-based AEs, such as skin rash can also be used (24).”
BackgroundBrown, J. R., Byrd, J. C., Coutre, S. E., Benson, D. M., Flinn, I. W., Wagner-Johnston, N. D., Spurgeon, S. E., Kahl, B. S., Bello, C., Webb, H. K., et al. (2014) · Blood · doi:10.1182/blood-2013-11-535047 · Cited by 590 · cited 2×
“Furthermore, tumor response, assessed by changes in tumor size, approached plateau in CLL and NHL patients at exposures obtained with a dose of 150mg twice a day (5, 27, 28), adding strong evidence to justify dose selection.”
BackgroundKurzrock, R., Sherman, S. I., Ball, D. W., Forastiere, A. A., Cohen, R. B., Mehra, R., Pfister, D. G., Cohen, E. E. W., Janisch, L., Nauling, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4145 · Cited by 550 · cited 6×
“org Clin Cancer Res; 22(6) March 15, 2016 1321”
BackgroundInfluentialLoRusso, P. M., Rudin, C. M., Reddy, J. C., Tibes, R., Weiss, G. J., Borad, M. J., Hann, C. L., Brahmer, J. R., Chang, I., Darbonne, W. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2745 · Cited by 544 · cited 1×
“In phase I, three dose levelswere administered (31): 150, 270, and540mg/d.”
Method
Research works printed but not linked: 1
- American Association for Cancer Research, 2015, Proceedings of the FDA-AACR Meeting (Dose-finding of small molecule oncology drugs); 2015 May 18–19
Cited by
Independent Drug Action in Combination Therapy: Implications for Precision Oncology
Plana, D., Palmer, A. C., & Sorger, P. K. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0212 · Cited by 307
“predicting some drug responses, for example, NTRK fusions and sensitivity”
Management of chronic myeloid leukemia in 2023 – common ground and common sense
Senapati, J., Sasaki, K., Issa, G. C., Lipton, J. H., Radich, J. P., Jabbour, E., & Kantarjian, H. M. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00823-9 · Cited by 176
“Originally, the TKIs (and many of the novel recent targeted therapies) were developed in strategies similar to the ones used for chemotherapy, at one dose lower than the maximum tolerated dose (MTD), which was based on the first 1-2 courses of therapy [73].”
MethodFourie Zirkelbach, J., Shah, M., Vallejo, J., Cheng, J., Ayyoub, A., Liu, J., Hudson, R., Sridhara, R., Ison, G., Amiri-Kordestani, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00371 · Cited by 186
TIGIT: a novel immunotherapy target moving from bench to bedside
Solomon, B. L., & Garrido-Laguna, I. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2246-5 · Cited by 200
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
Chatterjee, M., Turner, D. C., Felip, E., Lena, H., Cappuzzo, F., Horn, L., Garon, E. B., Hui, R., Arkenau, H.-T., Gubens, M. A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw174 · Cited by 172
“Recently, there has been considerable interest in optimizing dose selection for immunotherapies and other anticancer therapies [16, 17].”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- Sachs, J. R., Mayawala, K., Gadamsetty, S., Kang, S. P., & de Alwis, D. P.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- 2Department of PPDM-Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Rahway, New Jersey.
- Venue
- Clinical Cancer Research
- Published
- 2016-03-14
- Volume
- 22
- Issue
- 6
- Pages
- 1318-1324
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2173235643
- Cited by
- 159
- References
- 33
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 24 · 2023: 12 · 2022: 15 · 2021: 7 · 2020: 15 · 2019: 16 · 2018: 15 · 2017: 14 · 2016: 10
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Texas MD Anderson Cancer Center
- National Cancer Institute
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- targeted therapy, dose selection, dose-limiting toxicity, maximum tolerated dose, dose-ranging, pharmacodynamic biomarkers, target engagement, monoclonal antibodies, immunotherapy, anticancer drug development, hematologic malignancies, solid tumors
- MeSH terms
- Animals, Antineoplastic Agents, Dose-Response Relationship, Drug, Humans, Neoplasms, Prognosis, Biomarkers, Treatment Outcome, Maximum Tolerated Dose, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-1295
- The paper
- Sachs, J. R., Mayawala, K., Gadamsetty, S., Kang, S. P., & de Alwis, D. P. (2016). Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-1295
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.